These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 19195693)
1. Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age. Cho KS; Hwang TK; Kim BW; Yoon DK; Chang SG; Kim SJ; Park JY; Cheon J; Sung GT; Hong SJ; Urology; 2009 Apr; 73(4):828-32, 832.e1. PubMed ID: 19195693 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T; Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609 [TBL] [Abstract][Full Text] [Related]
3. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779 [TBL] [Abstract][Full Text] [Related]
4. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389 [TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621 [TBL] [Abstract][Full Text] [Related]
6. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431 [TBL] [Abstract][Full Text] [Related]
7. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471 [TBL] [Abstract][Full Text] [Related]
8. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171 [TBL] [Abstract][Full Text] [Related]
9. [Clinical investigation for recurrence and progression in Ta grades 1 and 2 bladder cancer]. Takei K; Kotake T; Masai M; Ito H; Nagao K; Chiba K; Saito K; Hirokawa M Hinyokika Kiyo; 1997 Mar; 43(3):185-9. PubMed ID: 9127752 [TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of bladder urothelial tumors in female patients. Zhang NZ; Chen J; Wang HQ; Xu ZS Menopause; 2010 Mar; 17(2):421-5. PubMed ID: 19713871 [TBL] [Abstract][Full Text] [Related]
12. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma? Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253 [TBL] [Abstract][Full Text] [Related]
13. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases. Guo CC; Fine SW; Epstein JI Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332 [TBL] [Abstract][Full Text] [Related]
14. Relationship between patient age and superficial transitional cell carcinoma characteristics. Shi B; Zhang K; Zhang J; Chen J; Zhang N; Xu Z Urology; 2008 Jun; 71(6):1186-90. PubMed ID: 18372010 [TBL] [Abstract][Full Text] [Related]
15. [Transitional cell carcinoma of the bladder: behavior in young adults]. Huguet Pérez J; Errando Smet C; Regalado Pareja R; Martínez de Hurtado J; Batista Miranda E; Chéchile Toniolo G; Bazarri JS; Vicente Rodríguez J Arch Esp Urol; 1996; 49(6):607-12. PubMed ID: 8929103 [TBL] [Abstract][Full Text] [Related]
16. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855 [TBL] [Abstract][Full Text] [Related]
17. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. Bol MG; Baak JP; Buhr-Wildhagen S; Kruse AJ; Kjellevold KH; Janssen EA; Mestad O; Øgreid P J Urol; 2003 Apr; 169(4):1291-4. PubMed ID: 12629345 [TBL] [Abstract][Full Text] [Related]
18. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341 [TBL] [Abstract][Full Text] [Related]
20. Histopathological aspects of transitional cell carcinoma of the bladder: analysis of 20 years experience. Sciarra A; De Matteis A; Mariotti G; Voria G; Lucera R; Di Silverio F Int J Urol; 2004 Jul; 11(7):467-75. PubMed ID: 15242354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]